S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Price, News & Analysis

$4.54
+0.03 (+0.66%)
(As of 03/28/2024 ET)
Today's Range
$4.38
$4.68
50-Day Range
$3.82
$5.14
52-Week Range
$3.03
$10.30
Volume
126,802 shs
Average Volume
180,570 shs
Market Capitalization
$96.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.33

Achieve Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
259.4% Upside
$16.33 Price Target
Short Interest
Bearish
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Achieve Life Sciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.57) to ($1.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

774th out of 939 stocks

Diagnostic Substances Industry

11th out of 13 stocks

ACHV stock logo

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

ACHV Stock Price History

ACHV Stock News Headlines

Q4 2023 Achieve Life Sciences Inc Earnings Call
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Recap: Achieve Life Sciences Q4 Earnings
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
ACHV Apr 2024 2.500 call
How AI Is Saving Lives
ACHV: ORCA-OL to Start 2Q:24
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/16/2023
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.33
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+259.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.46 per share

Miscellaneous

Free Float
20,743,000
Market Cap
$96.22 million
Optionable
Optionable
Beta
1.32
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Richard A. B. Stewart (Age 65)
    Executive Chairman
    Comp: $575k
  • Mr. John A. Bencich M.B.A. (Age 47)
    CEO & Director
    Comp: $733.12k
  • Dr. Cindy Jacobs M.D. (Age 66)
    Ph.D., President, Chief Medical Officer & Director
    Comp: $614.25k
  • Mr. Jerry Wan (Age 42)
    Principal Accounting Officer
  • Dr. Anthony Clarke (Age 68)
    Chief Scientific Officer
    Comp: $546k
  • Ms. Jaime Xinos
    Executive Vice President of Commercial

ACHV Stock Analysis - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price target for 2024?

3 brokers have issued twelve-month price targets for Achieve Life Sciences' shares. Their ACHV share price targets range from $11.00 to $20.00. On average, they anticipate the company's share price to reach $16.33 in the next twelve months. This suggests a possible upside of 259.4% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How have ACHV shares performed in 2024?

Achieve Life Sciences' stock was trading at $4.12 at the beginning of the year. Since then, ACHV stock has increased by 10.3% and is now trading at $4.5450.
View the best growth stocks for 2024 here
.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 701,800 shares, an increase of 9.1% from the February 29th total of 643,200 shares. Based on an average daily trading volume, of 92,000 shares, the days-to-cover ratio is presently 7.6 days.
View Achieve Life Sciences' Short Interest
.

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACHV earnings forecast
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same quarter in the prior year, the firm posted ($0.76) earnings per share.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.86%), Vanguard Group Inc. (2.86%), Raymond James & Associates (0.73%), Northern Trust Corp (0.48%), Madison Park Capital Advisors LLC (0.05%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHV) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners